AstraZeneca Pharma India shares saw a rise after Imfinzi got approval for expanded use. The CDSCO approved it as a first-line treatment for specific endometrial cancer cases. This follows AstraZeneca’s strong Q4 earnings, with a significant jump in net profit and revenue. The company attributes this to its focus on innovation.
Groww’s Ishan Bansal sees structural shift in derivatives participation post regulatory changes
Derivatives business faces a structural reset post FY25 regulatory changes, with growth now driven by a smaller but stable customer base, increased market volatility, and
April 21, 2026